RxDoctor Payments Data

Jihad Jiha, MD

Interventional Pain Medicine · Baton Rouge, LANPI 1114997723

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (60.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 19.8%.

$16,524in general payments, 2019–2025

Across 359 payments — averaging $46.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$3K
  • Abbott$3K
  • Relievant Medsystems, Inc.$2K
  • Nevro Corp.$2K
  • Vertiflex, Inc.$1K
  • Boston Scientific$1K
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$6,53740%
  • Food & beverage$9,91460%
  • Education$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,524 in reported general payments places this provider in the 75th percentile of 57 interventional pain medicine providers in Louisiana.

See all interventional pain medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$97,986
Medicare patients
260
Services billed
1,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl35$26,086
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen705$12,570
MovantikNaloxegol Oxalate18$12,161
Xtampza ErOxycodone Myristate20$12,020
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen323$7,507
Buprenorphine22$6,880
Gabapentin448$5,461
Topiramate325$3,564
Tizanidine Hcl274$2,519
Tramadol Hcl ErTramadol Hcl31$2,115
Fentanyl13$2,076
Tramadol Hcl262$1,559
Duloxetine Hcl85$1,354
Pregabalin98$1,251
Methocarbamol133$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$468$38,10655 claims
Upsher-smith Laboratories LLCTopiramate$12$3,564325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 interventional pain medicine providers in Louisiana.

Other interventional pain medicine in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →